Literature DB >> 2823499

Characterization of an Epstein-Barr virus nuclear antigen 2 variant (EBNA 2B) by specific sera.

M Sauter1, N Mueller-Lantzsch.   

Abstract

The Jijoye Epstein-Barr virus (EBV) strain is characterized by a substitution of 1.8 kb in the C-terminal part of EBNA 2 gene compared to B95-8 or M-ABA virus. Protein immunoblot analysis using human sera against EBNA 2 indicated that an immunological variant to the EBNA 2 of B95-8 (type A) is encoded by the Jijoye virus (type B). In order to generate a specific EBNA 2B antiserum the NaeI/NsiI DNA fragment of the Jijoye virus containing 237 bp of the C-terminus from the EBNA 2B gene was cloned in an E. coli expression vector (pME3). The resulting fusion protein contained 79 C-terminal amino acids of the viral protein and a 37,000 Da part of the bacterial anthranilate synthase. Rabbit antisera generated against this fusion protein reacted specifically with two proteins of 73,000 and 77,000 Da from Jijoye cells and three other cell lines carrying type B virus, while no proteins could be identified in the type B cell line BL 29. In addition, using these sera directed against the pME3 fusion protein, no reaction could be observed with the EBNA 2A protein from the B95-8 and several other cell lines containing type A virus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823499     DOI: 10.1016/0168-1702(87)90025-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.

Authors:  Wei Yue; Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Biochemical characterization of Epstein-Barr virus nuclear antigen 2A.

Authors:  F A Grässer; P Haiss; S Göttel; N Mueller-Lantzsch
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies.

Authors:  F Pratesi; C Tommasi; C Anzilotti; I Puxeddu; E Sardano; G Di Colo; P Migliorini
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

4.  Immunological study of the nef protein from HIV-1 by polyclonal and monoclonal antibodies.

Authors:  N Kienzle; M Bröker; H P Harthus; M Enders; V Erfle; M Buck; N Müller-Lantzsch
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera.

Authors:  B Frech; U Zimber-Strobl; K O Suentzenich; O Pavlish; G M Lenoir; G W Bornkamm; N Mueller-Lantzsch
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Expression of the HIV-1 Nef protein in the baculovirus system: investigation of anti-Nef antibodies response in human sera and subcellular localization of Nef.

Authors:  N Kienzle; M Enders; M Buck; H Siakkou; S Jahn; G Petzold; K E Schneweis; M Bachmann; W E Müller; N Müller-Lantzsch
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.

Authors:  R Geertsen; A Espander-Jansson; M Dobec; P Price; W Wunderli; L Rymo
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

8.  Mitosis-specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function.

Authors:  Wei Yue; Matthew G Davenport; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas.

Authors:  M Sauter; S Schommer; E Kremmer; K Remberger; G Dölken; I Lemm; M Buck; B Best; D Neumann-Haefelin; N Mueller-Lantzsch
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.